CytomX Therapeutics, Inc.
CTMX · XNASCIK 1501989fmd_13SDJ99F6RFJ97SPV1868QE2NDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
Latest annual · FY2025
Millions- Total revenues
- 76
- Operating income
- (22)
- Net income
- (17)
- Free cash flow
- (76)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 2
- Operating income
- (24)
- Net income
- (20)
- Free cash flow
- 16
Daily close · CTMXIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions2.14 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +12.8%
- Revenue, 5 yearsFY2020 to FY2025
- +2.2%
- Net income, 5 yearsFY2020 to FY2025
- n/m
CytomX Therapeutics, Inc. (CTMX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $76.2 million | $138.1 million | -44.8% | 10-K 2026-03-16 · proof |
| Operating income | -$22.4 million | $25 million | -189.5% | 10-K 2026-03-16 · proof |
| Net income | -$17.4 million | $31.9 million | -154.5% | 10-K 2026-03-16 · proof |
| Cash from operating activities | -$75.6 million | -$86.2 million | 10-K 2026-03-16 · proof | |
| Free cash flow | -$75.8 million | -$86.5 million | 10-K 2026-03-16 · proof | |
| Total assets | $151.6 million | $120.5 million | +25.7% | 10-K 2026-03-16 · proof |
| Total liabilities | $52.6 million | $121 million | -56.6% | 10-K 2026-03-16 · proof |
| Cash and cash equivalents | $12.7 million | $38.1 million | -66.7% | 10-K 2026-03-16 · proof |
- What was CytomX Therapeutics, Inc. (CTMX)'s revenue in fiscal 2025?
- CytomX Therapeutics, Inc. (CTMX) reported revenue of $76.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $138.1 million the year before (-44.8%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was CytomX Therapeutics, Inc. (CTMX)'s operating income in fiscal 2025?
- CytomX Therapeutics, Inc. (CTMX) reported operating income of -$22.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $25 million the year before (-189.5%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was CytomX Therapeutics, Inc. (CTMX)'s net income in fiscal 2025?
- CytomX Therapeutics, Inc. (CTMX) reported net income of -$17.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $31.9 million the year before (-154.5%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was CytomX Therapeutics, Inc. (CTMX)'s cash from operating activities in fiscal 2025?
- CytomX Therapeutics, Inc. (CTMX) reported cash from operating activities of -$75.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$86.2 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was CytomX Therapeutics, Inc. (CTMX)'s free cash flow in fiscal 2025?
- CytomX Therapeutics, Inc. (CTMX) reported free cash flow of -$75.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$86.5 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are CytomX Therapeutics, Inc. (CTMX)'s total assets?
- As of Dec 31, 2025, CytomX Therapeutics, Inc. (CTMX) reported total assets of $151.6 million, against $120.5 million a year earlier (+25.7%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are CytomX Therapeutics, Inc. (CTMX)'s total liabilities?
- As of Dec 31, 2025, CytomX Therapeutics, Inc. (CTMX) reported total liabilities of $52.6 million, against $121 million a year earlier (-56.6%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are CytomX Therapeutics, Inc. (CTMX)'s cash and cash equivalents?
- As of Dec 31, 2025, CytomX Therapeutics, Inc. (CTMX) reported cash and cash equivalents of $12.7 million, against $38.1 million a year earlier (-66.7%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:CTMX&period_type=annual&limit=5"Information only, not investment advice.